Fulgent Genetics (NASDAQ:FLGT) Issues Earnings Results, Beats Estimates By $0.56 EPS

Fulgent Genetics (NASDAQ:FLGT) posted its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.56, FiscalAI reports. The business had revenue of $90.41 million during the quarter, compared to the consensus estimate of $86.30 million. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%.

Here are the key takeaways from Fulgent Genetics’ conference call:

• Third-quarter revenue rose 8% year over year to $90.4 million, with Anatomic Pathology up 57% and BioPharma Services up 5%; growth was primarily driven by the integration of Bako and StrataDx. Precision Diagnostics declined 18% year over year.
• Management reported improving collections after billing-system customizations helped lift third-quarter revenue and gross margin sequentially. The transition is not complete, however, and management said further work is needed before collections return to historical levels.
• Fulgent narrowed its 2026 non-GAAP loss-per-share outlook to $1.65–$1.75 from $2.22–$2.35, and raised its projected year-end cash, restricted cash, and marketable securities to about $630 million. The cash increase chiefly reflects a $112.3 million federal tax refund and related interest.
• The company reported progress in its oncology pipeline: FID-007’s Phase II is mostly complete, with a Phase III study in preparation, while FID-022 is in Phase I dose escalation. These programs remain clinical-stage and their commercial prospects are uncertain.
• Fulgent’s AI platform analyzed about 255,000 slide images in Q3, up 23% sequentially, and analysis failures fell to 0.01%; five additional AI applications are planned for Q4. Management said the technology could improve quality and productivity, though it did not quantify a current financial benefit.

Fulgent Genetics Stock Up 27.2%

Shares of Fulgent Genetics stock traded up $5.08 during trading on Friday, reaching $23.74. 1,097,340 shares of the stock were exchanged, compared to its average volume of 274,766. The firm has a market cap of $653.09 million, a price-to-earnings ratio of -7.68 and a beta of 1.00. Fulgent Genetics has a 1 year low of $13.46 and a 1 year high of $31.04. The stock’s fifty day moving average is $20.80 and its 200 day moving average is $19.31.

Wall Street Analysts Forecast Growth

FLGT has been the topic of a number of recent research reports. Wall Street Zen raised Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Saturday. Piper Sandler boosted their target price on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.50.

Insider Buying and Selling

In related news, COO Jian Xie sold 2,127 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total transaction of $41,816.82. Following the completion of the transaction, the chief operating officer owned 359,924 shares in the company, valued at $7,076,105.84. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,673 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total value of $32,891.18. Following the completion of the sale, the insider directly owned 986,117 shares of the company’s stock, valued at $19,387,060.22. The trade was a 0.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 5,932 shares of company stock worth $117,156. Corporate insiders own 36.18% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.